Side effects of ATG/ALG treatment for aplastic anemia
Part of Blood & lymphatic clinical trials.
This study looks at the side effects of a medicine called ATG or ALG, which is given to calm the immune system in people with aplastic anemia. It may help doctors better understand and manage these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with aplastic anemia (a condition where your body stops making enough blood cells).
- You are about to receive ATG or ALG therapy for the first time.
- You have not had a stem cell transplant before.
- You are not receiving ATG or ALG as part of a stem cell transplant preparation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two first treatments for severe aplastic anemia: a half-matched (haploidentical) stem cell transplant versus immune-suppressing medicine. It is for people aged 14–70 who do not have a fully matched sibling donor.
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Hear when a new Aplastic Anaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.